TrueBinding

TrueBinding, Inc. was founded in 2016 as a clinical-stage biotherapeutics company creating new and exciting molecules for applications in neurodegenerative diseases (AD, PD, ALS), stroke, metabolic disorders, oncology, and other areas with significant unmet medical needs. Based on its proprietary Truebinding™ platform, TrueBinding has discovered over six novel drug targets to date and developed potentially game-changing monoclonal antibody therapeutics.